{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:53:05Z","timestamp":1780987985301,"version":"3.54.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12185-026-04165-7","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T17:43:11Z","timestamp":1769535791000},"page":"496-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel agents and therapeutic advances in T cell lymphoma"],"prefix":"10.1007","volume":"123","author":[{"given":"Yuko","family":"Shirouchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0654-6920","authenticated-orcid":false,"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"25","key":"4165_CR1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4165_CR2","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/bjh.12659","volume":"164","author":"D Chihara","year":"2014","unstructured":"Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164(4):536\u201345.","journal-title":"Br J Haematol"},{"key":"4165_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.01124","volume":"11","author":"M Iwanaga","year":"2020","unstructured":"Iwanaga M. Epidemiology of HTLV-1 infection and ATL in Japan: an update. Front Microbiol. 2020;11:1124.","journal-title":"Front Microbiol"},{"issue":"10168","key":"4165_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340.","journal-title":"Lancet"},{"issue":"16","key":"4165_CR5","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970\u20136.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4165_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/hon.2705","volume":"38","author":"H Ma","year":"2020","unstructured":"Ma H, Cheng B, Falchi L, Marchi E, Sawas A, Bhagat G, et al. Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials. Hematol Oncol. 2020;38(1):51\u20138.","journal-title":"Hematol Oncol"},{"key":"4165_CR7","unstructured":"Haematolymphoid Tumours: WHO Classification of Tumours, 5th Edition. IARC; 2024"},{"issue":"2","key":"4165_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ng.2872","volume":"46","author":"M Sakata-Yanagimoto","year":"2014","unstructured":"Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(2):171\u20135.","journal-title":"Nat Genet"},{"issue":"4","key":"4165_CR9","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","volume":"102","author":"MP Dobay","year":"2017","unstructured":"Dobay MP, Lemonnier F, Missiaglia E, Bastard C, Vallois D, Jais JP, et al. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica. 2017;102(4):e148\u201351.","journal-title":"Haematologica"},{"issue":"19","key":"4165_CR10","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","volume":"123","author":"J Iqbal","year":"2014","unstructured":"Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915\u201323.","journal-title":"Blood"},{"issue":"19","key":"4165_CR11","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","volume":"123","author":"T Wang","year":"2014","unstructured":"Wang T, Feldman AL, Wada DA, Lu Y, Polk A, Briski R, et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood. 2014;123(19):3007\u201315.","journal-title":"Blood"},{"issue":"11","key":"4165_CR12","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1182\/blood.2021015019","volume":"140","author":"TA Herek","year":"2022","unstructured":"Herek TA, Bouska A, Lone W, Sharma S, Amador C, Heavican TB, et al. DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS. Blood. 2022;140(11):1278\u201390.","journal-title":"Blood"},{"issue":"6","key":"4165_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631\u20136.","journal-title":"J Clin Oncol"},{"key":"4165_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-11","volume":"7","author":"B Coiffier","year":"2014","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7:11.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"4165_CR15","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s12185-017-2286-1","volume":"106","author":"D Maruyama","year":"2017","unstructured":"Maruyama D, Tobinai K, Ogura M, Uchida T, Hatake K, Taniwaki M, et al. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I\/II and pharmacokinetics study. Int J Hematol. 2017;106(5):655\u201365.","journal-title":"Int J Hematol"},{"key":"4165_CR16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280996","author":"S Rai","year":"2022","unstructured":"Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, et al. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica. 2022. https:\/\/doi.org\/10.3324\/haematol.2022.280996.","journal-title":"Haematologica"},{"issue":"8","key":"4165_CR17","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1111\/cas.15431","volume":"113","author":"A Utsunomiya","year":"2022","unstructured":"Utsunomiya A, Izutsu K, Jo T, Yoshida S, Tsukasaki K, Ando K, et al. Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia\/lymphoma: phase IIb results. Cancer Sci. 2022;113(8):2778\u201387.","journal-title":"Cancer Sci"},{"issue":"12","key":"4165_CR18","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/S1470-2045(24)00502-3","volume":"25","author":"D Maruyama","year":"2024","unstructured":"Maruyama D, Jacobsen E, Porcu P, Allen P, Ishitsuka K, Kusumoto S, et al. Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study. Lancet Oncol. 2024;25(12):1589\u2013601.","journal-title":"Lancet Oncol"},{"issue":"12","key":"4165_CR19","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/S1470-2045(24)00503-5","volume":"25","author":"PL Zinzani","year":"2024","unstructured":"Zinzani PL, Izutsu K, Mehta-Shah N, Barta SK, Ishitsuka K, C\u00f3rdoba R, et al. Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2024;25(12):1602\u201313.","journal-title":"Lancet Oncol"},{"issue":"10","key":"4165_CR20","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood.2022016862","volume":"141","author":"K Izutsu","year":"2023","unstructured":"Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, et al. An open-label, single-arm, phase 2 trial of valemetostat in relapsed or Refractory adult T-Cell Leukemia\/Lymphoma. Blood. 2023;141(10):1159\u201368.","journal-title":"Blood"},{"issue":"4","key":"4165_CR21","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hon.2320","volume":"35","author":"B Pro","year":"2017","unstructured":"Pro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, et al. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematol Oncol. 2017;35(4):914\u20137.","journal-title":"Hematol Oncol"},{"issue":"19","key":"4165_CR22","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","volume":"4","author":"P Ghione","year":"2020","unstructured":"Ghione P, Faruque P, Mehta-Shah N, Seshan V, Ozkaya N, Bhaskar S, et al. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma. Blood Adv. 2020;4(19):4640\u20137.","journal-title":"Blood Adv"},{"issue":"21","key":"4165_CR23","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","volume":"132","author":"F Lemonnier","year":"2018","unstructured":"Lemonnier F, Dupuis J, Sujobert P, Tournillhac O, Cheminant M, Sarkozy C, et al. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood. 2018;132(21):2305\u20139.","journal-title":"Blood"},{"issue":"17","key":"4165_CR24","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood.2019001285","volume":"134","author":"OA O'Connor","year":"2019","unstructured":"O\u2019Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood. 2019;134(17):1395\u2013405.","journal-title":"Blood"},{"issue":"6","key":"4165_CR25","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S2352-3026(24)00102-9","volume":"11","author":"J Dupuis","year":"2024","unstructured":"Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, et al. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study. Lancet Haematol. 2024;11(6):e406\u201314.","journal-title":"Lancet Haematol"},{"issue":"13","key":"4165_CR26","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","volume":"49","author":"F Morschhauser","year":"2013","unstructured":"Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer. 2013;49(13):2869\u201376.","journal-title":"Eur J Cancer"},{"issue":"5","key":"4165_CR27","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/cncr.29103","volume":"121","author":"E Toumishey","year":"2015","unstructured":"Toumishey E, Prasad A, Dueck G, Chua N, Finch D, Johnston J, et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer. 2015;121(5):716\u201323.","journal-title":"Cancer"},{"issue":"34","key":"4165_CR28","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","volume":"34","author":"T Ishida","year":"2016","unstructured":"Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, et al. Multicenter Phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002. J Clin Oncol. 2016;34(34):4086\u201393.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4165_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/hon.2712","volume":"38","author":"H Sakamoto","year":"2020","unstructured":"Sakamoto H, Itonaga H, Sawayama Y, Furumoto T, Fujioka M, Chiwata M, et al. Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki transplant group experience. Hematol Oncol. 2020;38(2):162\u201370.","journal-title":"Hematol Oncol"},{"issue":"3","key":"4165_CR30","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/hon.3115","volume":"41","author":"T Tanaka","year":"2023","unstructured":"Tanaka T, Inamoto Y, Ito A, Watanabe M, Takeda W, Aoki J, et al. Lenalidomide treatment for recurrent adult T-cell leukemia\/lymphoma after allogeneic hematopoietic cell transplantation. Hematol Oncol. 2023;41(3):389\u201395.","journal-title":"Hematol Oncol"},{"key":"4165_CR31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-203577","author":"N Mehta-Shah","year":"2024","unstructured":"Mehta-Shah N, Zinzani PL, Jacobsen ED, Zain J, Mead M, Casulo C, et al. Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma: final results from the phase 2 PRIMO trial. Blood. 2024. https:\/\/doi.org\/10.1182\/blood-2024-203577.","journal-title":"Blood"},{"issue":"9","key":"4165_CR32","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41591-024-03076-6","volume":"30","author":"SM Horwitz","year":"2024","unstructured":"Horwitz SM, Nirmal AJ, Rahman J, Xu R, Drill E, Galasso N, et al. Duvelisib plus romidepsin in relapsed\/refractory T cell lymphomas: a phase 1b\/2a trial. Nat Med. 2024;30(9):2517\u201327.","journal-title":"Nat Med"},{"issue":"8","key":"4165_CR33","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","volume":"131","author":"SM Horwitz","year":"2018","unstructured":"Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, et al. Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888\u201398.","journal-title":"Blood"},{"issue":"26","key":"4165_CR34","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood.2021013379","volume":"138","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828\u201337.","journal-title":"Blood"},{"issue":"1","key":"4165_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","volume":"25","author":"Y Song","year":"2024","unstructured":"Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, et al. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study. Lancet Oncol. 2024;25(1):117\u201325.","journal-title":"Lancet Oncol"},{"issue":"11","key":"4165_CR36","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.annonc.2023.08.013","volume":"34","author":"Y Song","year":"2023","unstructured":"Song Y, Yoon DH, Yang H, Cao J, Ji D, Koh Y, et al. Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas. Ann Oncol. 2023;34(11):1055\u201363.","journal-title":"Ann Oncol"},{"issue":"6","key":"4165_CR37","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1080\/10428194.2025.2455489","volume":"66","author":"SM Horwitz","year":"2025","unstructured":"Horwitz SM, Feldman TA, Ye JC, Khodadoust MS, Munoz J, Hamlin PA, et al. Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase\/janus kinase inhibitor, in relapsed\/refractory peripheral T-cell lymphoma. Leuk Lymphoma. 2025;66(6):1100\u201310.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"4165_CR38","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O'Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182\u20139.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4165_CR39","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1111\/cas.13340","volume":"108","author":"D Maruyama","year":"2017","unstructured":"Maruyama D, Nagai H, Maeda Y, Nakane T, Shimoyama T, Nakazato T, et al. Phase I\/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci. 2017;108(10):2061\u20138.","journal-title":"Cancer Sci"},{"issue":"11","key":"4165_CR40","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1182\/bloodadvances.2023010441","volume":"8","author":"OA O\u2019Connor","year":"2024","unstructured":"O\u2019Connor OA, Ko BS, Wang MC, Maruyama D, Song Y, Yeoh EM, et al. Pooled analysis of pralatrexate single-agent studies in patients with relapsed\/refractory peripheral T-cell lymphoma. Blood Adv. 2024;8(11):2601\u201311.","journal-title":"Blood Adv"},{"issue":"1","key":"4165_CR41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00277-018-3418-2","volume":"98","author":"D Maruyama","year":"2019","unstructured":"Maruyama D, Tsukasaki K, Uchida T, Maeda Y, Shibayama H, Nagai H, et al. Multicenter phase 1\/2 study of forodesine in patients with relapsed peripheral T cell lymphoma. Ann Hematol. 2019;98(1):131\u201342.","journal-title":"Ann Hematol"},{"issue":"12","key":"4165_CR42","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1111\/cas.14671","volume":"111","author":"R Fukano","year":"2020","unstructured":"Fukano R, Mori T, Sekimizu M, Choi I, Kada A, Saito AM, et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial. Cancer Sci. 2020;111(12):4540\u20137.","journal-title":"Cancer Sci"},{"issue":"17","key":"4165_CR43","doi-asserted-by":"publisher","first-page":"4903","DOI":"10.1182\/bloodadvances.2022008615","volume":"7","author":"WS Kim","year":"2023","unstructured":"Kim WS, Fukuhara N, Yoon DH, Yamamoto K, Uchida T, Negoro E, et al. Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study. Blood Adv. 2023;7(17):4903\u201312.","journal-title":"Blood Adv"},{"issue":"18","key":"4165_CR44","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190\u20136.","journal-title":"J Clin Oncol"},{"issue":"25","key":"4165_CR45","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","volume":"130","author":"B Pro","year":"2017","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709\u201317.","journal-title":"Blood"},{"issue":"20","key":"4165_CR46","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","volume":"123","author":"SM Horwitz","year":"2014","unstructured":"Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O\u2019Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095\u2013100.","journal-title":"Blood"},{"issue":"16","key":"4165_CR47","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","volume":"10","author":"T Ishida","year":"2004","unstructured":"Ishida T, Inagaki H, Utsunomiya A, Takatsuka Y, Komatsu H, Iida S, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res. 2004;10(16):5494\u2013500.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4165_CR48","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","volume":"32","author":"M Ogura","year":"2014","unstructured":"Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157\u201363.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4165_CR49","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.146977","volume":"101","author":"PL Zinzani","year":"2016","unstructured":"Zinzani PL, Karlin L, Radford J, Caballero D, Fields P, Chamuleau ME, et al. European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed\/refractory peripheral T-cell lymphoma. Haematologica. 2016;101(10):e407-e10.","journal-title":"Haematologica"},{"issue":"10","key":"4165_CR50","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1111\/cas.13343","volume":"108","author":"T Ishida","year":"2017","unstructured":"Ishida T, Utsunomiya A, Jo T, Yamamoto K, Kato K, Yoshida S, et al. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: updated follow-up analysis of phase I and II studies. Cancer Sci. 2017;108(10):2022\u20139.","journal-title":"Cancer Sci"},{"issue":"5","key":"4165_CR51","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3324\/haematol.2018.205096","volume":"104","author":"AA Phillips","year":"2019","unstructured":"Phillips AA, Fields PA, Hermine O, Ramos JC, Beltran BE, Pereira J, et al. Mogamulizumab versus investigator\u2019s choice of chemotherapy regimen in relapsed\/refractory adult T-cell leukemia\/lymphoma. Haematologica. 2019;104(5):993\u20131003.","journal-title":"Haematologica"},{"key":"4165_CR52","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027902","author":"M Yoshimitsu","year":"2025","unstructured":"Yoshimitsu M, Choi I, Kusumoto S, Shimokawa M, Utsunomiya A, Suehiro YD, et al. A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia\/lymphoma. Blood. 2025. https:\/\/doi.org\/10.1182\/blood.2024027902.","journal-title":"Blood"},{"issue":"28","key":"4165_CR53","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","volume":"34","author":"S Fuji","year":"2016","unstructured":"Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426\u201333.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4165_CR54","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.bbmt.2016.05.017","volume":"22","author":"T Sugio","year":"2016","unstructured":"Sugio T, Kato K, Aoki T, Ohta T, Saito N, Yoshida S, et al. Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22(9):1608\u201314.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"4165_CR55","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1111\/cas.14906","volume":"112","author":"H Kawai","year":"2021","unstructured":"Kawai H, Ando K, Maruyama D, Yamamoto K, Kiyohara E, Terui Y, et al. Phase II study of E7777 in Japanese patients with relapsed\/refractory peripheral and cutaneous T-cell lymphoma. Cancer Sci. 2021;112(6):2426\u201335.","journal-title":"Cancer Sci"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04165-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04165-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04165-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:01:32Z","timestamp":1776258092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04165-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4165"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04165-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yuko Shirouchi has received honoraria from Johnson & Johnson, Chugai, Ezai, Meiji, Sanofi, Nippon Shinyaku, and BMS. Dai Maruyama has received research funding from Ono, Janssen, Eisai, Chugai, Kyowa Kirin, MSD, Sanofi, Symbio, Takeda, AbbVie, AstraZeneca, BMS, Genmab, Novartis, Otsuka, Pfizer, Astellas, BeOne, Eli Lilly, Daiichi-Sankyo, Meiji Seika Pharma, honoraria from Ono, Nippon Shinyaku, Janssen, Mundipharma, Eisai, Chugai, Roche, Kyowa Kirin, MSD, Zenyaku, Sanofi, Symbio, Takeda, AbbVie, AstraZeneca, BMS, Genmab, Novartis, BeOne, and consultancy from Janssen, AstraZeneca, Chugai, AbbVie, Genmab, Sanofi, BMS, Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}